COVID-19: SARS-CoV-2-CZ-PREVAL-II Study

CompletedOBSERVATIONAL
Enrollment

7,268

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

February 24, 2022

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
DIAGNOSTIC_TEST

Quantitative analysis of SARS-CoV-2 antibodies

The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).

DIAGNOSTIC_TEST

Cellular immunity

Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.

Trial Locations (1)

128 01

Institute of Health Information and Statistics of the Czech Republic, Prague

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ministry of Health, Czech Republic

OTHER_GOV

collaborator

The National Institute of Public Health

UNKNOWN

collaborator

The Institute of Molecular and Translational Medicine, Czech Republic

OTHER

collaborator

University Hospital Olomouc

OTHER

collaborator

Institute for Clinical and Experimental Medicine

OTHER_GOV

collaborator

Thomayer University Hospital

OTHER

collaborator

Czech Academy of Sciences

OTHER

collaborator

Palacky University

OTHER

lead

Institute of Health Information and Statistics of the Czech Republic

OTHER_GOV